We propose to consider R2TP as a therapeutic target, as a role for R2TP in intestinal carcinogenesis is supported by several lines of evidences: (i) a higher expression of mRNAs encoding R2TP subunits in colorectal tumors, as compared to matching controls, (ii) high RPAP3 protein levels in biopsies of CRC patients with poor diagnostic, (iii) a strong dependency on RPAP3 in the proliferative compartment, and (iv) sensitivity of cell proliferation in a p53-dependent and independent context. The gene discussed is RPAP3; the disease is colorectal carcinoma.